scholarly journals NMR Spectroscopy-Based Metabolomics of Platelets to Analyze Brain Tumors

Reports ◽  
2021 ◽  
Vol 4 (4) ◽  
pp. 32
Author(s):  
Shivanand Pudakalakatti ◽  
Alessandra Audia ◽  
Anirudh Mukhopadhyay ◽  
José S. Enriquez ◽  
Dontrey Bourgeois ◽  
...  
Keyword(s):  
Nuclear Magnetic Resonance ◽  
Brain Tumor ◽  
Nmr Spectroscopy ◽  
Pilot Study ◽  
Brain Tumors ◽  
Healthy Volunteers ◽  
Tumor Patients ◽  
Diagnosis Of Cancer ◽  
Altered Metabolism ◽  
Substantial Interest

“Tumor-educated platelets” have recently generated substantial interest for the diagnosis of cancer. We hypothesized that tumor educated platelets from patients with brain tumors will reflect altered metabolism compared to platelets from healthy volunteers. Here, in a pilot study, we have employed nuclear magnetic resonance (NMR) spectroscopy in platelets from brain tumor patients to demonstrate altered metabolism compared to the platelets obtained from healthy volunteers.

scholarly journals Genetic variants and cognitive functions in patients with brain tumors

2019 ◽  
Vol 21 (10) ◽  
pp. 1297-1309 ◽  
Author(s):  
Denise D Correa ◽  
Jaya Satagopan ◽  
Axel Martin ◽  
Erica Braun ◽  
Maria Kryza-Lacombe ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Cell Cycle ◽  
Dna Repair ◽  
Brain Tumor ◽  
Brain Tumors ◽  
Cell Cycle Regulation ◽  
Cognitive Outcome ◽  
Cholesterol Transport ◽  
Tumor Patients ◽  
Cycle Regulation

AbstractBackgroundPatients with brain tumors treated with radiotherapy (RT) and chemotherapy (CT) often experience cognitive dysfunction. We reported that single nucleotide polymorphisms (SNPs) in the APOE, COMT, and BDNF genes may influence cognition in brain tumor patients. In this study, we assessed whether genes associated with late-onset Alzheimer’s disease (LOAD), inflammation, cholesterol transport, dopamine and myelin regulation, and DNA repair may influence cognitive outcome in this population.MethodsOne hundred and fifty brain tumor patients treated with RT ± CT or CT alone completed a neurocognitive assessment and provided a blood sample for genotyping. We genotyped genes/SNPs in these pathways: (i) LOAD risk/inflammation/cholesterol transport, (ii) dopamine regulation, (iii) myelin regulation, (iv) DNA repair, (v) blood–brain barrier disruption, (vi) cell cycle regulation, and (vii) response to oxidative stress. White matter (WM) abnormalities were rated on brain MRIs.ResultsMultivariable linear regression analysis with Bayesian shrinkage estimation of SNP effects, adjusting for relevant demographic, disease, and treatment variables, indicated strong associations (posterior association summary [PAS] ≥ 0.95) among tests of attention, executive functions, and memory and 33 SNPs in genes involved in: LOAD/inflammation/cholesterol transport (eg, PDE7A, IL-6), dopamine regulation (eg, DRD1, COMT), myelin repair (eg, TCF4), DNA repair (eg, RAD51), cell cycle regulation (eg, SESN1), and response to oxidative stress (eg, GSTP1). The SNPs were not significantly associated with WM abnormalities.ConclusionThis novel study suggests that polymorphisms in genes involved in aging and inflammation, dopamine, myelin and cell cycle regulation, and DNA repair and response to oxidative stress may be associated with cognitive outcome in patients with brain tumors.

scholarly journals Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors

Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1546 ◽  
Author(s):  
Alena Kopkova ◽  
Jiri Sana ◽  
Tana Machackova ◽  
Marek Vecera ◽  
Lenka Radova ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Brain Tumor ◽  
Brain Tumors ◽  
Low Grade ◽  
Tumor Type ◽  
Tumor Patients ◽  
Primary Tumors ◽  
Mirna Profiling ◽  
Tumor Types ◽  
Cns Malignancies

Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be highly stable and resistant to even extreme conditions. The overall aim of our study was to identify specific CSF miRNA patterns that could differentiate among brain tumors. These new biomarkers could potentially aid borderline or uncertain imaging results onto diagnosis of CNS malignancies, avoiding most invasive procedures such as stereotactic biopsy or biopsy. In total, 175 brain tumor patients (glioblastomas, low-grade gliomas, meningiomas and brain metastases), and 40 non-tumor patients with hydrocephalus as controls were included in this prospective monocentric study. Firstly, we performed high-throughput miRNA profiling (Illumina small RNA sequencing) on a discovery cohort of 70 patients and 19 controls and identified specific miRNA signatures of all brain tumor types tested. Secondly, validation of 9 candidate miRNAs was carried out on an independent cohort of 105 brain tumor patients and 21 controls using qRT-PCR. Based on the successful results of validation and various combination patterns of only 5 miRNA levels (miR-30e, miR-140, let-7b, mR-10a and miR-21-3p) we proposed CSF-diagnostic scores for each tumor type which enabled to distinguish them from healthy donors and other tumor types tested. In addition to this primary diagnostic tool, we described the prognostic potential of the combination of miR-10b and miR-196b levels in CSF of glioblastoma patients. In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.

Hypersensitivity reactions to teniposide (VM-26): an analysis.

1986 ◽  
Vol 4 (8) ◽  
pp. 1262-1269 ◽  
Author(s):  
P J O'Dwyer ◽  
S A King ◽  
C L Fortner ◽  
B Leyland-Jones
Keyword(s):  
Brain Tumor ◽  
Brain Tumors ◽  
Literature Search ◽  
Hematologic Malignancies ◽  
Survey Method ◽  
Hypersensitivity Reactions ◽  
Tumor Patients ◽  
True Incidence ◽  
Drug Doses ◽  
Insight Into

An analysis of hypersensitivity reactions to teniposide was approached using three methods: investigator survey, adverse drug reaction analysis, and literature search. By the survey method, hypersensitivity incidence was 6.5% with the majority of the reactions (82%) occurring in brain tumor or neuroblastoma patients. By the second method, 43 cases of hypersensitivity that were reported to the National Cancer Institute (NCI) between January 1983 and October 1985 were analyzed in detail. Reaction onset was unpredictable according to the number of drug doses. The majority of the patients (65%) experiencing the reaction had neuroblastoma or brain tumors, and these patients also tended to react earlier in the course of drug administration than those with hematologic malignancies. Clinical presentation was not correlated with the patient's diagnosis. All patients recovered. However, only six of 13 were successfully rechallenged with the drug. The third approach, the literature search, provided information on 82 hypersensitivity reactions among 2,250 patients (3.6% incidence). Forty-five percent of these reactions were linked to neuroblastoma or brain tumor patients. The analysis of hypersensitivity to teniposide by these three methods provides insight into the true incidence of hypersensitivity reactions in the general patient population. The frequency of the reactions is substantially higher in patients with neuroblastoma and brain tumors. This population should be considered for future trials of aggressive prophylactic therapy.

scholarly journals Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism

Blood ◽  
2017 ◽  
Vol 129 (13) ◽  
pp. 1831-1839 ◽  
Author(s):  
Julia Riedl ◽  
Matthias Preusser ◽  
Pegah Mir Seyed Nazari ◽  
Florian Posch ◽  
Simon Panzer ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Venous Thromboembolism ◽  
Platelet Aggregation ◽  
High Risk ◽  
Brain Tumors ◽  
Tumor Patients ◽  
Primary Brain Tumors ◽  
Key Points ◽  
Podoplanin Expression ◽  
Very High

Key Points Brain tumor patients have a very high risk of VTE. Podoplanin expression by primary brain tumors induces platelet aggregation and is associated with hypercoagulability and a high risk of VTE.

Association of thyroid hormone concentrations with quality of life of primary brain tumor patients: a pilot study

2016 ◽  
Vol 131 (2) ◽  
pp. 385-391 ◽  
Author(s):  
Adomas Bunevicius ◽  
Edward R. Laws ◽  
Vytenis Deltuva ◽  
Arimantas Tamasauskas
Keyword(s):  
Quality Of Life ◽  
Brain Tumor ◽  
Pilot Study ◽  
Thyroid Hormone ◽  
Primary Brain Tumor ◽  
Tumor Patients

scholarly journals Study Protocol for a Randomized Controlled Trial Evaluating the Efficacy of an Evidence-Based iPad-App for Cognitive Rehabilitation in Patients with Primary Brain Tumors

Neurosurgery ◽  
2018 ◽  
Vol 85 (2) ◽  
pp. 273-279 ◽  
Author(s):  
Sophie Dorothee van der Linden ◽  
Margriet Maria Sitskoorn ◽  
Geert-Jan Maria Rutten ◽  
Karin Gehring
Keyword(s):  
Randomized Controlled Trial ◽  
Brain Tumor ◽  
Brain Tumors ◽  
Cognitive Rehabilitation ◽  
Controlled Trial ◽  
Rehabilitation Program ◽  
Control Group ◽  
Tumor Patients ◽  
Primary Brain Tumors ◽  
Randomized Controlled

Abstract BACKGROUND Many patients with primary brain tumors suffer from cognitive deficits, which negatively impact their quality of life. However, cognitive rehabilitation programs for these patients are scarce. We developed an iPad-based cognitive rehabilitation program for brain tumor patients, which was based on our effective face-to-face cognitive rehabilitation program. After successful completion of a feasibility study, a randomized controlled trial has been started. OBJECTIVE To evaluate the immediate and long-term effects of the iPad-based program on cognitive performance and patient-reported outcome measures (PROMs) in patients with primary brain tumors in an early stage of the disease. METHODS Prior to surgery, patients with presumed low-grade glioma and meningioma are included. Before surgery and 3 mo after surgery, neuropsychological assessments are conducted. After the second neuropsychological assessment, patients are assigned to the intervention group or waiting-list control group. The intervention consists of psychoeducation, compensation training, and retraining. Patients are advised to spend 3 h per week on the program for 10 wk. Immediately after completion of the program and a half-year thereafter, postintervention assessments take place. Patients in the control group are offered the opportunity to follow the program after all study assessments. EXPECTED OUTCOMES We expect that early cognitive rehabilitation has beneficial effects on cognitive performance and PROMs in brain tumor patients. DISCUSSION The iPad-based program allows brain tumor patients to follow a cognitive rehabilitation program from their homes. Forthcoming results may contribute to further improvement of supportive care for brain tumor patients.

scholarly journals Biomarkers and focused ultrasound: the future of liquid biopsy for brain tumor patients

2021 ◽  
Author(s):  
Jordina Rincon-Torroella ◽  
Harmon Khela ◽  
Anya Bettegowda ◽  
Chetan Bettegowda
Keyword(s):  
Brain Tumor ◽  
Brain Tumors ◽  
Liquid Biopsy ◽  
Focused Ultrasound ◽  
Modern Medicine ◽  
Detection Methods ◽  
Liquid Biopsies ◽  
Tumor Patients ◽  
Clinical Trial Registries ◽  
Increased Risk

Abstract Introduction Despite advances in modern medicine, brain tumor patients are still monitored purely by clinical evaluation and imaging. Traditionally, invasive strategies such as open or stereotactic biopsies have been used to confirm the etiology of clinical and imaging changes. Liquid biopsies can enable physicians to noninvasively analyze the evolution of a tumor and a patient’s response to specific treatments. However, as a consequence of biology and the current limitations in detection methods, no blood or cerebrospinal fluid (CSF) brain tumor-derived biomarkers are used in routine clinical practice. Enhancing the presence of tumor biomarkers in blood and CSF via brain-blood barrier (BBB) disruption with MRI-guided focused ultrasound (MRgFUS) is a very compelling strategy for future management of brain tumor patients. Methods A literature review on MRgFUS-enabled brain tumor liquid biopsy was performed using Medline/Pubmed databases and clinical trial registries. Results The therapeutic applications of MRgFUS to target brain tumors have been under intense investigation. At high-intensity, MRgFUS can ablate brain tumors and target tissues, which needs to be balanced with the increased risk for damage to surrounding normal structures. At lower-intensity and pulsed-frequency, MRgFUS may be able to disrupt the BBB transiently. Thus, while facilitating intratumoral or parenchymal access to standard or novel therapeutics, BBB disruption with MRgFUS has opened the possibility of enhanced detection of brain tumor-derived biomarkers. Conclusions In this review, we describe the concept of MRgFUS-enabled brain tumor liquid biopsy and present the available preclinical evidence, ongoing clinical trials, limitations, and future directions of this application.

scholarly journals NCMP-01. RISK FACTORS ASSOCIATED WITH LATE HYPERGLYCEMIA IN BRAIN TUMOR PATIENTS WITH POSTOPERATIVE ADMINISTRATION OF DEXAMETHASONE

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi179-vi179
Author(s):  
Seung Ho Yang
Keyword(s):  
Brain Tumor ◽  
Blood Glucose ◽  
Brain Tumors ◽  
Fasting Blood Glucose ◽  
Smoking History ◽  
Diabetic Patients ◽  
Tumor Patients ◽  
Corticosteroid Administration ◽  
Glucose Levels ◽  
Diabetes Patients

Abstract Dexamethasone is the corticosteroid most commonly used for the management of vasogenic edema in patients with brain tumors. The occurrence of hyperglycemia following corticosteroid administration is well known to physicians and health care givers. The purpose of the study is to investigate late onset of hyperglycemia and associated factors in patients with brain tumors. The inclusion criteria are as follows; 1) brain tumor patients underwent craniotomy; 2) steroid administered for at least 3 days longer perioperatively or postoperatively; 3) serum glucose levels examined for at least 3 months postoperatively The exclusion criteria are as follows; 1) steroid administered for less than 3 days; 2) patients diagnosed with type 1 diabetes, renal failure, hepatic failure or autoimmune diseases; 3) other medical illness treated with corticosteroid. A total of 101 patients were enrolled for the analysis. Fasting blood glucose of diabetes patients and non-diabetes patients was 160±93 mg/dl and 114±43 mg/dl, respectively. There was no difference of type of brain tumors, body mass index, hypertension, smoking history, hyperlipidemia, GOT, GPT, ESR, CRP, and Cr between diabetes patients and non-diabetes patients. The peak of Fasting blood glucose was noted on day 1 postoperatively in non-diabetes patients. Two peak of Fasting glucose levels were found on day 1 and 6 postoperatively in diabetes patients. Late hyperglycemia was determined as in patients with fasting blood glucose of >125 mg/dl during 3~6 months postoperatively. Fifteen patients out of 86 non-diabetes patients developed late hyperglycemia. There were significant differences of duration and total dose of dexamethasone administration between late hyperglycemia patients and non-late hyperglycemia patients. Steroid-induced hyperglycemia can develop late postoperatively even in non-diabetic patients with brain tumor treated with dexamethasone. Fasting blood glucose during the first week postoperatively can predict late hyperglycemia. Duration and total dosage of dexamethasone administered are associated with late hyperglycemia.

Differential levels of stress in caregivers of brain tumor patients—observations from a pilot study

2006 ◽  
Vol 14 (12) ◽  
pp. 1258-1261 ◽  
Author(s):  
Stephen T. Keir ◽  
Ann Bebe Guill ◽  
Karen E. Carter ◽  
Lindsay C. Boole ◽  
Lazaro Gonzales ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Pilot Study ◽  
Tumor Patients
Sign in / Sign up

Export Citation Format

Share Document